NMTC trades 10.2% above Wall Street's consensus target of $3.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes NMTC achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 2 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 30, 2026, NeuroOne Medical Technologies Corporation (NMTC) has a Wall Street consensus price target of $3.00, based on estimates from 2 covering analysts. With the stock currently trading at $3.34, this represents a potential downside of -10.2%. The company has a market capitalization of $29M.
Analyst price targets range from a low of $3.00 to a high of $3.00, representing a 0% spread in expectations. The median target of $3.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 1 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, NMTC trades at a trailing P/E of -6.2x. Analysts expect EPS to grow +84.1% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
LIVNLivaNova PLC | $4.6B | $83.06 | $81.43 | -2.0% | Buy | 19.5x | 15 |
NVCRNovoCure Limited | $1.8B | $15.48 | $33.00 | +113.2% | Buy | — | 15 |
MDTMedtronic plc | $103.9B | $80.93 | $95.80 | +18.4% | Buy | 13.6x | 51 |
ABTAbbott Laboratories | $161.5B | $92.71 | $126.00 | +35.9% | Buy | 16.9x | 41 |
BSXBoston Scientific Corporation | $64.6B | $43.48 | $82.40 | +89.5% | Buy | 12.9x | 44 |
INVAInnoviva, Inc. | $1.7B | $23.14 | $37.00 | +59.9% | Buy | 6.5x | 10 |
ITRIItron, Inc. | $3.7B | $83.72 | $136.80 | +63.4% | Hold | 14.0x | 37 |
ANIKAnika Therapeutics, Inc. | $201M | $15.01 | — | — | Buy | — | 6 |
MLABMesa Laboratories, Inc. | $550M | $99.53 | $94.00 | -5.6% | Hold | 11.0x | 8 |
ATECAlphatec Holdings, Inc. | $1.4B | $9.50 | $18.00 | +89.5% | Buy | 29.7x | 18 |
Quick answers to the most common questions about buying NMTC stock.
NMTC's consensus price target is $3, -10.2% below the current price of $3.34. The 2 analysts tracking NMTC see downside risk at present valuations.
NMTC has a consensus rating of "Buy" based on 2 Wall Street analysts. The rating breakdown is mixed, with 1 Hold ratings making up the largest segment. The consensus 12-month price target of $3 implies -10.2% downside from current levels.
NMTC's current price is $3.34 with a consensus target of $3 (-10.2% implied move). Analyst estimates suggest the stock is overvalued at current levels.
The most bullish Wall Street analyst has a price target of $3 for NMTC, while the most conservative target is $3. The consensus of $3 represents the median expectation. These targets typically reflect 12-month expectations.
NMTC is lightly followed, with 2 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 1 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month NMTC stock forecast based on 2 Wall Street analysts shows a consensus price target of $3, with estimates ranging from $3 (bear case) to $3 (bull case). The median consensus rating is "Buy".
Analysts are cautious on NMTC, with 0 Sell ratings and a price target of $3 (-10.2% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
NMTC analyst price targets range from $3 to $3, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $3 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.